Peroxisome proliferator-activated receptor-δ activates endothelial progenitor cells to induce angio-myogenesis through matrix metallo-proteinase-9- mediated insulin-like growth factor-1 paracrine networks

European Heart Journal

Volumn 34, Issue 23, 2013, Pages 1755-1765

  Han, Jung Kyu ^a   Kim, Hack Lyoung ^a   Jeon, Ki Hyun ^a   Choi, Young Eun ^a   Lee, Hyun Sook ^a   Kwon, Yoo Wook ^a   Jang, Ja June ^a   Cho, Hyun Jai ^a   Kang, Hyun Jae ^a   Oh, Byung Hee ^a   Park, Young Bae ^a   Kim, Hyo Soo ^a  

^a Seoul National University   (South Korea)

Author keywords

Agnio myogenesis; Endothelial progenitor cell; Peroxisome proliferator activated receptor

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; GELATINASE B; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; HINDLIMB; HUMAN; HUMAN CELL; ISCHEMIA; MOUSE; MUSCLE REGENERATION; MYOBLAST; NONHUMAN; NORMAL HUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SKELETAL MUSCLE; SYSTEMIC THERAPY; TARGET CELL; TRANSCRIPTION INITIATION; UMBILICAL VEIN ENDOTHELIAL CELL; WOUND HEALING;

AGNIO-MYOGENESIS; ENDOTHELIAL PROGENITOR CELL; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-Δ;

ANALYSIS OF VARIANCE; ANIMALS; CELL PROLIFERATION; ENDOTHELIAL CELLS; HETEROGRAFTS; HINDLIMB; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; ISCHEMIA; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT; MICE, NUDE; MONOCYTES; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; PPAR DELTA; RECEPTOR, IGF TYPE 1; REPERFUSION INJURY; STEM CELL TRANSPLANTATION; STEM CELLS; THIAZOLES;

EID: 84879116291     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr365     Document Type: Article

References (30)

1. Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006;116:590-597.
2. Han JK, Lee HS, Yang HM, Hur J, Jun SI, Kim JY, Cho CH, Koh GY, Peters JM, Park KW, Cho HJ, Lee HY, Kang HJ, Oh BH, Park YB, Kim HS. Peroxisome proliferator-activated receptor-delta agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway. Circulation 2008;118:1021-1033.
3. He T, Lu T, d'Uscio LV, Lam CF, Lee HC, Katusic ZS. Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells. Circ Res 2008;103: 80-88.
4. Brunelli L, Cieslik KA, Alcorn JL, Vatta M, Baldini A. Peroxisome proliferatoractivated receptor-delta upregulates 14-3-3 epsilon in human endothelial cells via CCAAT/enhancer binding protein-beta. Circ Res 2007;100:e59-e71.
5. Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, Hatae T, Tanabe T, Warner TD, Bishop-Bailey D. Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol 2007;27:63-69.
6. Conti E, Carrozza C, Capoluongo E, Volpe M, Crea F, Zuppi C, Andreotti F. Insulin-like growth factor-1 as a vascular protective factor. Circulation 2004;110: 2260-2265.
7. Philippou A, Halapas A, Maridaki M, Koutsilieris M. Type I insulin-like growth factor receptor signaling in skeletal muscle regeneration and hypertrophy. J Musculoskelet Neuronal Interact 2007;7:208-218.
8. Kelley KM, Schmidt KE, Berg L, Sak K, Galima MM, Gillespie C, Balogh L, Hawayek A, Reyes JA, Jamison M. Comparative endocrinology of the insulin-like growth factor-binding protein. J Endocrinol 2002;175:3-18.
9. Baxter RC. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol 2001;54:145-148.
10. Fowlkes JL, Enghild JJ, Suzuki K, Nagase H. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J Biol Chem 1994;269:25742-25746.
11. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
12. Overall CM, Kleifeld O. Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227-239.
13. Manes S, Llorente M, Lacalle RA, Gomez-Mouton C, Kremer L, Mira E, Martinez AC. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem 1999;274:6935-6945.
14. Miyamoto S, Yano K, Sugimoto S, Ishii G, Hasebe T, Endoh Y, Kodama K, Goya M, Chiba T, Ochiai A. Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res 2004;64:665-671.
15. Yoon CH, Hur J, Park KW, Kim JH, Lee CS, Oh IY, Kim TY, Cho HJ, Kang HJ, Chae IH, Yang HK, Oh BH, Park YB, Kim HS. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation 2005;112:1618-1627.
16. Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 2001;98:5306-5311.
17. Blau HM, Pavlath GK, Hardeman EC, Chiu CP, Silberstein L, Webster SG, Miller SC, Webster C. Plasticity of the differentiated state. Science 1985;230: 758-766.
18. Hegele RA. Retinoid X receptor heterodimers in the metabolic syndrome. N Engl J Med 2005;353:2088.
19. Shearer BG, Steger DJ, Way JM, Stanley TB, Lobe DC, Grillot DA, Iannone MA, Lazar MA, Willson TM, Billin AN. Identification and characterization of a selectiveperoxisome proliferator-activated receptor beta/delta (NR1C2) antagonist. Mol Endocrinol 2008;22:523-529.
20. Corbel SY, Lee A, Yi L, Duenas J, Brazelton TR, Blau HM, Rossi FM. Contribution of hematopoietic stem cells to skeletal muscle. Nat Med 2003;9:1528-1532.
21. Madeddu P, Emanueli C, Pelosi E, Salis MB, Cerio AM, Bonanno G, Patti M, Stassi G, Condorelli G, Peschle C. Transplantation of low dose CD34+KDR+ cells promotes vascular and muscular regeneration in ischemic limbs. FASEB J 2004;18:1737-1739.
22. Rehman J, Li J, Orschell CM, March KL. Peripheral blood 'endothelial progenitor cells' are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003;107:1164-1169.
23. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-967.
24. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000;105:71-77.
25. Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, Mortell K, Pollok K, Ferkowicz MJ, Gilley D, Yoder MC. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004;104:2752-2760.
26. Ehrenborg E, Krook A. Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor delta. Pharmacol Rev 2009;61: 373-393.
27. Wang D, Wang H, Guo Y, Ning W, Katkuri S, Wahli W, Desvergne B, Dey SK, DuBois RN. Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc Natl Acad Sci U S A 2006; 103:19069-19074.
28. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, Crystal RG, Besmer P, Lyden D, Moore MA, Werb Z, Rafii S. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002;109:625-637.
29. Han YP, Tuan TL, Hughes M, Wu H, Garner WL. Transforming growth factorbeta-and tumor necrosis factor-alpha-mediated induction and proteolytic activation of MMP-9 in human skin. J Biol Chem 2001;276:22341-22350.
30. Jogie-Brahim S, Feldman D, Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev 2009;30:417-437.